Blueprint Medicines Corp
BPMC129.460USD
0.000
Fechamento 10/10, 16:00（ET）Cotações atrasadas em 15 min
8.36BValor de mercado
PerdaP/L TTM
Mais detalhes de Blueprint Medicines Corp Empresa
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Informações de Blueprint Medicines Corp
Código da empresaBPMC
Nome da EmpresaBlueprint Medicines Corp
Data de listagemApr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Número de funcionários649
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 30
Endereço45 Sidney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02139
Telefone16173747580
Sitehttps://www.blueprintmedicines.com/
Código da empresaBPMC
Data de listagemApr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Executivos da empresa Blueprint Medicines Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+22.22%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+33.54%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-19.00%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-13.93%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-68.90%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de abr
Moeda: USDAtualizado em: dom, 6 de abr
FY2024Q3
FY2024Q2
FY2024Q1
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
113.13M
88.26%
Rest of the world
15.05M
11.74%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Product revenue
128.18M
100.00%
Collaboration, license and other revenue
1.00K
0.00%
Distribuição de ações
Atualizado em: qua, 13 de ago
Atualizado em: qua, 13 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Outro
63.83%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.90%
T. Rowe Price Associates, Inc.
8.28%
BlackRock Institutional Trust Company, N.A.
7.29%
Avoro Capital Advisors LLC
5.95%
Wellington Management Company, LLP
4.75%
Outro
63.83%
Tipos de investidores
Investidores
Proporção
Investment Advisor
42.13%
Hedge Fund
26.61%
Investment Advisor/Hedge Fund
24.80%
Research Firm
3.16%
Sovereign Wealth Fund
1.66%
Individual Investor
0.93%
Bank and Trust
0.78%
Pension Fund
0.78%
Venture Capital
0.41%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
701
68.81M
106.41%
-3.22M
2025Q1
702
71.75M
110.98%
-1.27M
2024Q4
657
69.17M
108.25%
-2.83M
2024Q3
644
67.12M
105.97%
-7.85M
2024Q2
622
68.23M
108.95%
-6.94M
2024Q1
615
67.81M
110.73%
-5.62M
2023Q4
612
65.87M
108.35%
-10.02M
2023Q3
602
66.47M
109.56%
-7.64M
2023Q2
614
65.78M
108.78%
-8.60M
2023Q1
625
65.63M
109.42%
-10.28M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
--
0%
-223.92K
-100.00%
T. Rowe Price Associates, Inc.
--
0%
-3.95M
-100.00%
BlackRock Institutional Trust Company, N.A.
--
0%
-182.70K
-100.00%
State Street Global Advisors (US)
--
0%
-453.14K
-100.00%
Geode Capital Management, L.L.C.
--
0%
+18.37K
-100.00%
Macquarie Investment Management
--
0%
-364.73K
-100.00%
AllianceBernstein L.P.
--
0%
-430.85K
-100.00%
Ver Mais
ETFs Relacionados
Atualizado em: qua, 6 de ago
Atualizado em: qua, 6 de ago
Nome
Proporção
ProShares Merger ETF
3.21%
AltShares Event-Driven ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.92%
Goldman Sachs Future Health Care Equity ETF
0.84%
Hypatia Women CEO ETF
0.73%
First Trust Mid Cap Growth AlphaDEX Fund
0.58%
iShares Russell 2000 Growth ETF
0.54%
WisdomTree BioRevolution Fund
0.49%
SoFi Next 500 ETF
0.45%
JPMorgan Fundamental Data Science Small Core ETF
0.43%
Ver Mais
ProShares Merger ETF
Proporção3.21%
AltShares Event-Driven ETF
Proporção1.43%
ProShares Ultra Nasdaq Biotechnology
Proporção0.92%
Goldman Sachs Future Health Care Equity ETF
Proporção0.84%
Hypatia Women CEO ETF
Proporção0.73%
First Trust Mid Cap Growth AlphaDEX Fund
Proporção0.58%
iShares Russell 2000 Growth ETF
Proporção0.54%
WisdomTree BioRevolution Fund
Proporção0.49%
SoFi Next 500 ETF
Proporção0.45%
JPMorgan Fundamental Data Science Small Core ETF
Proporção0.43%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
